
    
      This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative
      trial, in parallel groups. Patients will be stratified by clinical center and foveal
      thickness to be treated either Macugen or a sham injection. After 24 weeks, all patients will
      treated with Macugen until the end of the study at 54 weeks.
    
  